Skip to content
value.today

Helicon Therapeutics Inc.

Total raised
$50 M
1 round on record
Latest round
$50 M
May 2009
First round on record
May 2009
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Helicon Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2009$50 MNo. 1$50 to $250 million

Helicon Therapeutics Inc.: Raise no. 1, May 2009

Investors in this round

1 investor had bought by the notice of Jun 26, 2009: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$50 M of $50 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$25 million to $100 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kenneth E. Johns, Jr. · Executive Officer, Director
  • Tim Tully, PhD. · Executive Officer, Director
  • Jonathan Gelles, D. Phil. · Director
  • Kenneth Dart · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Excludes reasonable salaries paid to executive officers.”

Signed by Kenneth E. Johns, Jr., President. Newest notice filed Jun 26, 2009. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Helicon Therapeutics Inc. had revenue between $25 million and $100 million when it filed its newest notice of a funding round (Jun 2009).

    SEC Form D (revenue range) · Jun 2009

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2009

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Helicon Therapeutics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Helicon Therapeutics Inc.
NameRoleNamed in
Kenneth E. Johns, Jr.Executive officerJun 2009
Tim Tully, PhD.Executive officerJun 2009
Jonathan Gelles, D. Phil.DirectorJun 2009
Kenneth DartDirectorJun 2009
Kenneth E. Johns, Jr.DirectorJun 2009
Tim Tully, PhD.DirectorJun 2009